O Caixa Empreender Award atribuiu um valor de investimento adicional, no valor de 100 mil euros, ao projeto que mais se destacou de um conjunto de 7 startups, previamente selecionadas no âmbito dos programas de aceleração que contam com o apoio do Grupo CGD, BGI, Lisbon Challenge e ACT by COTEC. A Extremo Chem foi uma das startups presentes no Caixa Empreender. #thefuturefromscratch Mais sobre o objetivo deste evento em: http://bit.ly/1CzA5BV

1. 2 7 T H J A N U A R Y 2 0 1 5

2. Team
• Founders:
- Rita Ventura
- Eva Lourenço
- Christopher Maycock
- Based on 15 years of academic research
• Business development team:
- Pedro Vilarinho, COTEC Portugal
- Filipe Aguiar, 73100 – Infraventus
- Founded on November 2013
- Investor: Setenta e Três Mil e Cem, Lda.

3. ExtremoChem is a start-up company aiming at the
development and commercialisation of chemically
synthesised novel excipients for the stabilisation of
biologics.

4. Problem/Opportunity

5. Problem/Opportunity
Active Protein Inactive Protein
Heat and cold

6. Current solution: cold chain
Certified container
Manufacturers Patient
Distributors
Current solution issues:
temperature excursions
Degradation - loss of efficacy and safety

7. “Improved thermostability of
vaccines is an area of interest for
us”
Senior Director External Scientific Affairs,
Merck & Co., USA
Market need

8. Our solution
Archaeoglobus fulgidus
Hydrothermal vents
• Chemically synthesised analogues of protein
stabilising natural compounds with improved
stabilisation properties

9. Our solution
STABILISATION OF BIOPHARMACEUTICALS
Heat and cold
Active Protein Active Protein
Chemical Compound

10. Value Proposition
Synthesis of new compounds for stabilisation of
biopharmaceuticals over a wider range of
temperatures
PHARMACEUTICAL
INDUSTRY
Biopharmaceuticals efficacy and safety
guaranteed all over the world
• The costs of cold chain failure are estimated to be €5b

11. • Spin-off of the Imperial College London, 2007
• Excipient mixture derived from seeds and customised
to each vaccine - under testing
• Private company based in Cambridge, Massachusetts,
founded in 2001
• Liposome encapsulation of vaccine - under clinical
trials
Competition

12. Development status
• Stabilisation of commercially available biopharmaceuticals in the
presence of ExtremoChem compounds:
 Caninsulin – Porcine insulin, for veterinary use
 Lantus, Humulin Regular, Actrapid, Insuman Rapid, Insuman
Basal, Humulin NpH, Insulatard - Human Insulin
 Cervarix and Gardasil – Human papiloma virus vaccine
 Erythropoietin – Human, recombinant, CHO cells
 Norditropin SimpleXx – Somatropine, human growth hormone

13. Development status
• Stabilisation of biopharmaceuticals at room temperature for 10, 15
and 30 days in the presence of ExtremoChem compounds
• Degradation of the proteins at room temperature without added
compounds
• The biological activity of the proteins in the presence of our
compounds remained the same

14. IP Protection
• US Provisional Patent submitted during 2013: Hexose derivatives,
preparation and uses thereof
• IP Legal advisers: Cooper & Dunham LLP – New York
• PCT application under preparation
• New IP under preparation

15. Business model
• Co-development for each different indication with relevant
pharmaceutical companies
Optimised formulation for the stabilisation
of the Active Principle Ingredients (API’s)
• Revenue generated through licensing

16. Roadmap
2014 2015 2016 2017 2018 2019 ...
IP
Services/Colaborations
Insulins
R&D
2002…
Vaccines
Monoclonal antibodies & Epoetins
EMA
Toxicity
Tests
FDA &
IPEC

17. Summary
• ExtremoChem is a tech based start-up
• Commercialisation of new excipients – distribution of biopharmaceuticals
without the need of cold chain
• Active and safe biopharmaceuticals all over the world
• Addresses a recognised unmet market need

18. Thank you for your
attention!
Eva Lourenço, eva.lourenco@extremochem.com
Rita Ventura, rita.ventura@extremochem.com
Christopher Maycock, chris.maycock@extremochem.com
Pedro Vilarinho, pedro.vilarinho@cotec.pt
Filipe Aguiar, filipe.aguiar@infraventus.com